Document Classification

Section Type: RESULTS

Text: Overall, the rates of pathological complete response were 14. 9 % with epirubicin and cyclophosphamide followed by docetaxel and 18. 4 % with epirubicin and cyclophosphamide followed by docetaxel plus bevacizumab (odds ratio with addition of bevacizumab, 1. 29 ; 95 % confidence interval, 1. 02 to 1. 65 ; P = 0. 04) ; the corresponding rates of pathological complete response were 27. 9 % and 39. 3 % among 663 patients with triple-negative tumors (P = 0. 003) and 7. 8 % and 7. 7 % among 1262 patients with hormone-receptor-positive tumors (P = 1. 00).